**Topic: CCMA Advisory Council Meeting**

**Time: May 26, 2022 11:00 AM Eastern Time (US and Canada)**

**Join Zoom Meeting**

**https://us02web.zoom.us/j/87853892384?pwd=dGFVOFhJcGxhcUNvbXY0YjNjcURDUT09**

**Meeting ID: 878 5389 2384**

**Passcode: 4CZCsF**

**One tap mobile**

**+16475580588,,87853892384#,,,,\*526578# Canada**

**+17789072071,,87853892384#,,,,\*526578# Canada**

**Dial by your location**

**+1 647 558 0588 Canada**

**+1 778 907 2071 Canada**

**+1 204 272 7920 Canada**

**+1 438 809 7799 Canada**

**+1 587 328 1099 Canada**

**+1 647 374 4685 Canada**

**Meeting ID: 878 5389 2384**

**Passcode: 526578**

**Find your local number: https://us02web.zoom.us/u/kekWTUJv3a**

**CCMA - Advisory Council**

**May 26, 2022 – 11:00 AM Eastern/7:00 AM Pacific**

**Agenda**

1. ***Introductions***
2. ***Review/approve the Minutes of the meeting held on April 28, 2022***
3. ***PTM - Update/Discussion on***
   1. ***CDS Rebates – update***

1. ***Oversight Committee and PTM Project Update***
   1. ***Updated project timelines***
   2. ***Early Adopter testing update***
   3. ***Industry Testing update……see below***
2. ***Questions***
3. ***Next Meeting June 23, 2022 at 11:00 AM ET***

**CCMA - Advisory Council**

**April 28, 2022 –** **Minutes**

1. ***Introductions***

Keith Evans of CCMA welcomed attendees to the CCMA Advisory Council meeting. He asked all members attending by phone to send an email to him indicating their attendance at the meeting.

1. ***Review/Approve the Minutes from the March 21, 2022 meeting***

Keith reported that the Minutes from the last CCMA Advisory Council meeting, held on March 21, 2022, were distributed with the meeting package. There were no additions, subtractions or material corrections requested by members, therefore the Minutes of the meeting were approved as presented.

1. ***Update/Discussion on:***
2. ***CDS Rebate –*** Keith said that CDS had previously reported that they had submitted responses to the CSA, and that a review was underway. However, due to the uncertainty of the PTM project dates, this review is temporarily on hold until the project timelines become clearer.
3. ***Oversight Committee and Project Update:***
4. **Project Timelines** – Keith reported that as of the last monthly CDS meeting, that industry testing will now commence in June, another month delay from last month. The final implementation date is still scheduled for Q1 2023. He said that this seems difficult to envision a schedule like this given the number of outstanding issues still to be resolved. Cycle 1 of the CDS UAT is still only 98.5% complete, with four defects to be resolved. After the Cycle 1 is complete, a ‘clean’ Cycle 2 must be completed as well. At this time, the Cycle 2 is only about 35% complete. Additionally, any further delays in the implementation date will likely have material impacts on the T+1, if that project goes ahead with a March 2024 implementation timeline.
5. **Early Adopter testing** - Keith reported that Kyndryl, Broadridge, and Paramax had all completed as much Early Adopter testing as possible, except where outstanding defect remediation from CDS was still outstanding. Primarily, this includes CNS, Corporate Actions, Repos, and Buy Ins. Kyndryl has recently moved into “red’ status, due to outstanding defects at CDS. Paramax had indicated that currently they do not have the resource availability to do any retesting or additional Early Adopter testing should CDS correct the errors found by Paramax during their testing phase. Paramax has indicated that resources could become available in the Fall to accommodate more testing. Broadridge indicated that they are currently comfortable with their testing with CDS, but still have some code defects that need to be rectified before they will be able to complete their testing.
6. **Industry Testing** – Keith reported that CDS has indicated a June start of industry testing. This represents another one-month delay.

There was a very lengthy discussion around the status of the project. All of those that spoke mentioned their concern with the following issues being referred to by many.

* Lack of transparency by CDS on the outstanding issues
  + Need greater details on what are the issues being addressed and how close are they
* Lack of transparency on what it will take, in terms of time, to get to the beginning of industry testing
  + Monthly delays are adding to the industry’s lack of confidence in CDS
* CDS’s industry test plan is by design a ‘happy path’ plan. Which given the number of outstanding issues and constant delays, seem unrealistic and very concerning
  + There is real concern that the nine months assigned to industry testing is going to be nowhere near enough given the lack of trust in CDS to deliver a solid trustworthy system
* Member groups (maybe the banks, the BCSC local community group, IIROC Operations group) have all been in various discussions on how best to address the lack of confidence in the ability of CDS to bring this project to conclusion
* The ability of members to address concerns through the regulatory process
  + There will be a public comment period for any Rule and procedural change proposed by CDS, that require regulatory approval
* Does CDS need this to be completed in a certain timeline in order to launch other new products
  + Alternatively, can the current system run indefinitely?

1. ***Questions***

There were no additional questions not covered in the above agenda items.

1. ***Next Meeting***

The next meeting of the CCMA - Advisory Council will be scheduled for Tuesday May 26, 2022 at 11:00 AM Eastern.

|  |  |  |
| --- | --- | --- |
| **In Attendance** | **Firm** | **Name** |
|  |  |  |
| X | CCMA | Keith Evans Chair |
|  |  |  |
| X | AMF | Francis Coche |
|  |  | Veronic Boivin Pednault |
|  |  | Julie Boyer |
| X |  | Dilya Rasoulova Dilbarkan |
|  |  | Dominique Martin |
| X |  | Herman Tan |
|  | AGF | Mike Kwok |
|  | AST Trust | Mark Cohen |
|  | Bank of Canada | Christian Belisle |
|  |  | Romain Hubner |
|  |  | Fuwad Siddiqi |
|  |  | Mishra Ridima |
| X |  | Pooja Kumar |
| X |  | Andre Usche |
|  |  | Danika Cheff |
|  |  | Stefan Caputo |
|  | BCSC | Eric Thong |
|  |  | Rina Jaswal |
| X |  | Meg Tassie |
| X |  | Michael Brady |
|  |  | Michael Grecoff |
| X | BMO | Kal Kawfik |
|  |  | Paul White |
|  |  | Keri Peacock |
|  | Broadridge | Mary-Beth Law |
| X |  | Doug Gifford |
| X |  | Henry DeLange |
| X |  | Peter Wilkinson |
|  |  | Mo Akinsanya |
|  |  | Sahil Duggal |
|  | Canaccord | Simon Witney |
| X |  | Sheera Badial |
| X |  | Brenda McIntyre |
|  |  | Ralston Vazz |
| X | CBA | Hartland Elcock |
|  | Casgrain | Pierre Mital |
| X | CDS | Margaret Reid |
| X |  | Johann Lochner |
|  |  | Joseph Chau |
|  |  | Lucy Mullins |
| X |  | Daniel Farley |
| X | CETFA | Pat Dunwoody |
|  | CFA Societies | Michael Thom |
| X | CIBC - WM | Kapil Sharma |
| X |  | Greg Sutton |
|  |  | Danny Leca |
| X |  | Cathy Jones |
| X | CIBC Mellon | Carol Revoredo |
| X |  | Louis Lesnika |
| X |  | Laxman Natarajan |
|  | CI Investment | Deborah Carlyle |
|  | Computershare | Donna McLaughlin |
|  | Cooperators | Mehreen Hussain |
|  | Credit Suisse | Wayne Cowell |
| X |  | Ester Park |
| X |  | Connie Tam |
|  |  | Lavkesh Raval |
|  |  | Sam Farrell |
| X | Desjardins | Pascal Deslauriers |
|  | Edward Jones | Paul Camarata |
|  |  | Danielle Thebodo |
|  | ETC | Dianne Graham |
|  | Fidelity | Stephanie Leblanc-Mchenry |
| X |  | Rob Argue |
|  |  | Carol Perrault |
| X |  | Dan Brennan |
| X |  | Peter Burns |
|  |  | Chandra Maddula |
|  | FMFD | Matthew Latimer |
|  | Fundserv | Russ White |
|  | GMP Richardson | Andrew Burnett |
| X | Goldman Sachs | Anit Patel |
|  | Haywood | Peter Virvilis |
|  | IFDS | Grant Bellamy |
|  | IFIC | Pamela Egger |
| X | IIROC | Catherine Drennan |
| X | Kyndryl | Andrew Ledbury |
|  |  | Lisa Cousineau |
| X | Laurentian | Anne Claire Hurillon |
|  | Leede/Jones | Jim Dale |
|  | Manulife Inv | Bill Devolin |
|  | Merrill Lynch - BofA | Doug Butters |
|  |  | Bruna Dipietro |
| X | National Bank | Nelson Dugre-Sasseville |
|  |  | Anna Tyniec |
|  |  | Louis Philippe Pepin |
| X | Northern Trust | Domenic Sgambelluri |
|  | OSC | Aaron Ferguson |
| X |  | Franklin Lacroce |
|  | Paramax | Gary Stephenson |
|  |  | Allyn Howe |
|  | PWC | Samantha Paisley |
|  | Questrade | Lulu Feng |
|  |  | Thao Kha |
|  | RBC-IS | Jill Morrison |
|  |  | John Riordon |
| X |  | Eunice Kang |
|  |  | Kerry Phippen |
| X | RBC-WM | Jason O’Born |
|  | RF Clearing | Joe Riga |
|  | Scotiabank | Mike Bieley |
|  | SS&C | Paul Skuriat |
|  | Statestreet | Denny Mendoca |
|  |  | Adrian Chicayah |
|  |  | Ivan Yang |
| X |  | Lynn Freedman |
| X | TD Bank | Michael Kenny |
|  |  | Geoff Baxter |
|  |  | Kevin Fraites |
| X |  | Tim Stephenson |
| X |  | Kevin Calhoun |
|  |  | Tracey Randall |
|  |  | Elinor Young |
| X |  | James Mikelson |
|  |  | Rob Candido |
|  | TMX | Isaac Volonte |
|  | Torstone | Mack Gill |
|  |  | Daniel Geddes |
| X |  | Dave O’Marra |
| X | Consultant | Barb Amsden |
| X |  | Jeff Carr |

**Recommendations presented to the PTM Oversight Committee on May 11, 2022.**

|  |  |
| --- | --- |
| **Revisit Test Strategy, Training and Testing Execution** | |
| 1 | Reconfirm testing strategy against industry standards to incorporate defect cycles, improved transparency of bug and testing results |
| 2 | Solicit Industry participants to review and suggest enhancements to the test strategy. |
| 3 | Solicit Industry participants to review and suggest enhancements to the training plan. |
|  |  |
| **End to End Testing** | |
| 4 | Adjust project deliverables to accommodate completion of third party testing prior to initiation of Scripted testing |
| 5 | Address variances with third parties re: status of defect fixes and timelines to resolve |
| 6 | Support integrated testing with other third parties (DTCC, Fundserv, other Exchanges) |
|  |  |
| **Project Timelines** | |
| 7 | Provide updated project timelines to include non-happy path scenarios, defect cycles and contingencies. |
| 8 | Share holistic timeline that includes degree of anticipated intersection with T+1 |
|  |  |
| **Completeness/Quality of Deliverables** | |
| 9 | Reaffirm resource capabilities as program moves to Industry testing, publish SLA/turnaround time on defects |